FI
STML

Fosun International’s Stemline Therapeutics, Inc. STML Stock Holding History

Fosun International’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-212,936
Closed -$3.21M – 326
2019
Q2 		$3.21M Sell
212,936
-55,000
-21% -$796K 0.21% 72
2019
Q1 		$3.29M Buy
267,936
+209,936
+362% +$2.37M 0.21% 65
2018
Q4 		$572K Buy
+58,000
New +$752K 0.03% 201

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fosun International's STML Position: Q3 2019 in Review

Fosun International sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 212,936 shares — an estimated $3.21M sold.

Fosun International first reported a position in STML in Q4 2018 and held it in 3 quarters. The position peaked at $3.29M in Q1 2019. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • Fosun International reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 212,936 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $3.21M.
  • Fosun International first reported a position in Stemline Therapeutics, Inc. in Q4 2018 and held it in 3 quarters.
  • Fosun International's Stemline Therapeutics, Inc. position peaked at $3.29M in Q1 2019.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.